Relmada raises $160M private placement; NDV-01 12-month Phase 2 CR rate 76%

RELMADA THERAPEUTICS, INC.

Oversubscribed PIPE financing of ~$160M gross from 29.47M shares at $4.75/share plus pre-funded warrants, expected to close March 11, 2026.
Proceeds to be used for working capital and advancing R&D of product candidates, including NDV-01.
NDV-01 Phase 2 in high-risk NMIBC: 12-month complete response rate 76% overall, 80% in BCG-unresponsive patients.
No Grade 3+ treatment-related adverse events; no patient progressed to muscle-invasive disease or required cystectomy.
Phase 3 RESCUE program planned for mid-2026 with two registrational pathways: 2L BCG-unresponsive and adjuvant intermediate-risk NMIBC.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

RELMADA THERAPEUTICS, INC. issued 29,474,569 shares of common stock to certain institutional and accredited investors for $4.75 per Share.

Security: common stock
Shares: 29,474,569 shares
Purchaser: certain institutional and accredited investors
Consideration: $4.75 per Share

Exact text from the filing

of approximately $160.0 million, an aggregate of (i) 29,474,569 shares (“Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $4.75 per Share and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 4,210,527 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a price of $4.749 per

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

RELMADA THERAPEUTICS, INC. issued up to 4,210,527 shares of Common Stock of warrant to certain institutional and accredited investors for $4.749 per Pre-Funded Warrant.

Security: warrant
Shares: up to 4,210,527 shares of Common Stock
Purchaser: certain institutional and accredited investors
Consideration: $4.749 per Pre-Funded Warrant

Exact text from the filing

of approximately $160.0 million, an aggregate of (i) 29,474,569 shares (“Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $4.75 per Share and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 4,210,527 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a price of $4.749 per

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

RELMADA THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $160.0 million (effective 2026-03-09).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional and accredited investors
Value: approximately $160.0 million
Effective: 2026-03-09

Exact text from the filing

On March 9, 2026, Relmada Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).

View on SEC.gov

Browse all equity issuances →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-024918

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.